Today is an exciting day for Zoetis as we continue to provide innovations for veterinarians and pet owners alike! I am happy to share that the FDA has approved a new label indication for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets).…
In August, Zoetis informed us that they would begin rolling out new packaging for their vaccine line. Over the next few months, you’ll notice some changes happening to the Zoetis Petcare vaccines you use in your clinic. Some of these…
Zoetis today announced that the U.S. FDA has approved a new label indication for Simparica® (sarolaner) Chewables for the prevention of Borrelia burgdorferi in dogs. Simparica is now proven to block the pathogen that causes Lyme disease as a result of…
Download Link
Sharing some information with you on the new Imagyst in house fecal analyzer. The New In-House Fecal Analyzer uses the fecal centrifugation method to bring clinical pathology to the point of care. The IMAGYST recognizes through Artificial Intelligence, parasite…
PARSIPPANY, N.J.–(BUSINESS WIRE)–Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Simparica TrioTM (sarolaner, moxidectin, and pyrantel chewable tablets), the first once-monthly, chewable tablet in the U.S. that delivers all-in-one protection from heartworm disease, ticks and…
Zoetis will be sending direct communications including a letter and email message to all IsoFlo end-customers by July 28. If customers have any questions, they can contact the Zoetis Veterinary Medical Information and Product Support Team at 1-888-963-8471. Zoetis will…
The U.S. Food and Drug Administration (FDA) has approved ProHeart® 12 (moxidectin), the new, first-ever once-yearly injection to prevent heartworm disease (caused by Dirofilaria immitis) in dogs 12 months of age and older. Its unique formulation of moxidectin microspheres provides…